471 related articles for article (PubMed ID: 24726140)
21. Gastrointestinal stromal tumours (GISTs): case report and review of the literature.
Al-Amri AM; Shawarbi MA; El-Hassan AY; Al-Johi KS
Gulf J Oncolog; 2011 Jan; (9):57-60. PubMed ID: 21177210
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
23. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
25. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal stromal tumor: 15-years' experience in a single center.
Wang M; Xu J; Zhang Y; Tu L; Qiu WQ; Wang CJ; Shen YY; Liu Q; Cao H
BMC Surg; 2014 Nov; 14():93. PubMed ID: 25403624
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P
Eur J Cancer; 2015 May; 51(7):852-60. PubMed ID: 25801699
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
29. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
30. Multidisciplinary treatment of gastrointestinal stromal tumors.
Kingham TP; DeMatteo RP
Surg Clin North Am; 2009 Feb; 89(1):217-33, x. PubMed ID: 19186237
[TBL] [Abstract][Full Text] [Related]
31. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer.
Lai YH; Chen J; Wang XP; Wu YQ; Peng HT; Lin XH; Wang WJ
J Exp Clin Cancer Res; 2017 Jul; 36(1):92. PubMed ID: 28697793
[TBL] [Abstract][Full Text] [Related]
32. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?
Cananzi FC; Lorenzi B; Belgaumkar A; Benson C; Judson I; Mudan S
Langenbecks Arch Surg; 2014 Mar; 399(3):323-32. PubMed ID: 24413830
[TBL] [Abstract][Full Text] [Related]
34. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Reichardt P; Reichardt A
Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
[TBL] [Abstract][Full Text] [Related]
35. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer.
Ke Z; He W; Lai Y; Guo X; Chen S; Li S; Wang Y; Wang L
Oncotarget; 2014 Oct; 5(19):9410-24. PubMed ID: 25238260
[TBL] [Abstract][Full Text] [Related]
37. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
38. Surgical management of gastrointestinal stromal tumours: a single centre experience during the past 17 years.
De Vogelaere K; Van De Winkel N; Aerts M; Haentjens P; Spitali C; Van Loo I; Delvaux G
Acta Chir Belg; 2014; 114(3):167-73. PubMed ID: 25102705
[TBL] [Abstract][Full Text] [Related]
39. Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.
Zeng S; Seifert AM; Zhang JQ; Cavnar MJ; Kim TS; Balachandran VP; Santamaria-Barria JA; Cohen NA; Beckman MJ; Medina BD; Rossi F; Crawley MH; Loo JK; Maltbaek JH; Besmer P; Antonescu CR; DeMatteo RP
Mol Cancer Ther; 2017 Sep; 16(9):1954-1966. PubMed ID: 28611108
[TBL] [Abstract][Full Text] [Related]
40. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
Miranda C; Nucifora M; Molinari F; Conca E; Anania MC; Bordoni A; Saletti P; Mazzucchelli L; Pilotti S; Pierotti MA; Tamborini E; Greco A; Frattini M
Clin Cancer Res; 2012 Mar; 18(6):1769-76. PubMed ID: 22282465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]